Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL418 Administered Orally Daily to Subjects With Solid Tumors

NCT00460278 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT00460278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00460278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL418 Administered Orally Daily to Subjects With Solid Tumors
Lead sponsor
Exelixis
Phase
Phase 1
Overall status
Suspended
Start date
April 30, 2007
Completion date
Not reported
Enrollment
63 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, solid tumors